AbbVie reached a most‑favored‑nation pricing agreement with the White House and pledged substantial investments in U.S. manufacturing as part of the deal. The company said it will focus on improving access and lowering costs consistent with the administration’s MFN program; AbbVie’s announcement followed other large pharma companies that have negotiated similar agreements. AbbVie’s commitment includes a multi‑year manufacturing investment pledge and terms to align pricing in specified government programs. The deal signals continued engagement between large biopharma and U.S. policy makers on drug pricing frameworks and highlights how major manufacturers are negotiating access and domestic industrial commitments in exchange for pricing concessions.